Holen Sie sich die Stockscreener-App
1,084.65
1.87%
19.91
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$1,064.74
Offen:
$1072.26
24-Stunden-Volumen:
1.58M
Relative Volume:
0.52
Marktkapitalisierung:
$967.53B
Einnahmen:
$72.25B
Nettoeinkommen (Verlust:
$25.28B
KGV:
39.04
EPS:
27.781
Netto-Cashflow:
$10.37B
1W Leistung:
+6.46%
1M Leistung:
+24.92%
6M Leistung:
-1.78%
1J Leistung:
+49.56%
1-Tages-Spanne:
$1,069.90
$1,093.00
1-Wochen-Bereich:
$1,022.00
$1,093.00
52-Wochen-Spanne:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,084.99 | 949.47B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.00 | 554.09B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
214.93 | 376.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.62 | 295.69B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
186.96 | 290.30B | 60.48B | 10.40B | 8.05B | 3.3297 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Bestätigt | BofA Securities | Buy |
| 2025-12-15 | Bestätigt | Goldman | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-10 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-10-14 | Hochstufung | Erste Group | Hold → Buy |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly to Expand Vaccine Pipeline With Three Biotech Buyouts - Zacks Investment Research
Kailera’s three-pronged obesity shot shows promise in early trial - BioPharma Dive
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating - 富途牛牛
Eli Lilly Vaccine Push Fuels NYSE Composite Focus - Kalkine Media
GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game. - The Motley Fool
Analyst recommendations: Nvidia, Blackrock, Eli Lilly, Goldman Sachs, Lululemon… - marketscreener.com
Lilly To Buy Vaccine Company For Up To $1.55 Billion - Pulse 2.0
Eli Lilly to acquire Seattle-area biotech in $1.5 billion bet on next-generation shingles vaccine - GeekWire
Lilly Goes on $20 Billion Buying Spree as It Seeks Next Act - Yahoo Finance
Eli Lilly to acquire Seattle-area vaccine maker for $1.5 billion - The Seattle Times
Barclays Raises Target on Eli Lilly (LLY) After Strong Tirzepatide Growth - Insider Monkey
Trump declares perfect health after Walter Reed physical; Eli Lilly spends $4B on three vaccine developers; obesity leveling off in wealthy nations, still rising elsewhere – Morning Medical Update - Medical Economics
Eli Lilly acquires Novo Holdings-backed Limmatech for USD 780m - medwatch.com
Micron Was Worth Less Than $70 Billion Last Year—Now It's A $1 Trillion Company, Overtaking JPMorgan, Walmart And Eli Lilly - Yahoo Finance
Key facts: Lilly buys 3 vax for up to $4B; PCSK9↓88% LDL‑C↓62%; BofA up GLP‑1 - TradingView
Lilly Follows Upbeat Trials for Cholesterol Shot with $4B M&A Spree - The Daily Upside
GC Biopharma Sells U.S. Affiliate Curevo to Eli Lilly for 459.9 Billion Won - Businesskorea
Eli Lilly Set to Acquire Curevo, LimmaTech Biologics, and Vaccine Co. for $4 Billion - scanx.trade
Lilly buys three vaccine firms to target dementia and infection preventionCHOSUNBIZ - Chosunbiz
How The Eli Lilly (LLY) Narrative Is Evolving With GLP-1 Hopes And Obesity Market Doubts - Yahoo Finance
Eli Lilly Buys 3 Vaccine Companies for $3.8B - Powder & Bulk Solids
GC Green Cross Sells U.S. Affiliate Curevo to Eli Lilly - 아시아경제
Former Metro councilman and pastor accused in 'fraud scheme' to steal $200 million from drug company - News Channel 5 Nashville
Lilly spending nearly $4B to acquire three vaccine developers - Inside INdiana Business
Lilly Is Looking for Its Next Act Beyond the Weight-Loss Boom - Barron's
Lilly to acquire three vaccine developers for up to $3.83 billion By Investing.com - Investing.com Canada
Eli Lilly and Company to acquire 3 vaccine development companies for nearly $4 billion - WTHR
Eli Lilly Expands Vaccine Push With Deals Worth Up To $3.8B - Law360
Eli Lilly acquires three vaccine companies for infectious disease portfolio - Managed Healthcare Executive
Lilly goes on $20 billion buying spree as company seeks next act - The Daily Gazette
What's Going On With Eli Lilly Stock Tuesday?Eli Lilly (NYSE:LLY) - Benzinga
Lilly to buy three vaccine developers for up to $3.8 billion - MSN
Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion - marketscreener.com
Lilly Goes on $20 Billion Buying Spree as Company Seeks Next Act - Bloomberg.com
Lilly Gets Back Into the Vaccine Business With New Deals - marketscreener.com
LLY: Eli Lilly Acquires Three Vaccine Developers for $3.8 Billio - GuruFocus
Eli Lilly targets vaccines market with $3.8B acquisition of three biotech firms - Proactive financial news
Lilly buys three vaccine makers; PCSK9 base editor shows promise - BioWorld News
Early data for heart drug affirm Lilly’s billion-dollar bet on Verve - BioPharma Dive
Lilly dives into vaccine research with 3 biotech buyouts - BioPharma Dive
Eli Lilly spending $3.8 billion to buy vaccine makers - Axios
Healthcare Takeovers Tick Pass $140 Billion After Latest Lilly Spree - Bloomberg.com
Lilly goes on $21B buying spree to build drug pipeline - dailyjournal.net
Lilly to buy three vaccine developers for nearly US$4 billion in infectious disease push - CTV News
Eli Lilly and Co. splashes out $3.8 billion to acquire three companies, aiming to get a head start in the next round of the global vaccine race - 富途牛牛
Eli Lilly announces acquisition of 3 vaccine makers in $4 billion deal - upi.com
Analyst recommendations: Eli Lilly, AutoZone, BP plc, Ferrari, Samsung Electronics… - marketscreener.com
Positive Clinical Data for Eli Lilly's Gene Editing Therapy VERVE-102 - GuruFocus
Eli Lilly Bets Nearly $4 Billion on Vaccines: Is the Weight-Loss Drug Giant’s Next Growth Curve Here? - TradingKey
Lilly Expands Into Vaccines With Three Infectious Disease Acquisitions Worth Up to $3.8 Billion - citybiz
Lilly to Acquire Vaccine Company in $1.55 Billion Bet on Epstein-Barr Vaccine Development - citybiz
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.07%
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):